Valsartan: Many antihypertensive drugs from seven laboratories are withdrawn from sale

National Administration of Drugs, Food and Drug medical technologies
(Anmat) said it ordered the withdrawal of the sale of more than 300 batches of drugs with the drug Valsartan, which is indicated to treat hypertension and reduce the risk of heart attack or accident cerebrovascular.

The regulatory authority has provided a list that can be accessed
here, with the number of antihypertensive batches from seven local laboratories with the active substance contaminated with N-nitrosodimethylamine (NDMA), a substance that can cause cancer. The product comes from a laboratory in China

Over the past two weeks, the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA) and the authorities of La Public Health in Canada issued similar alerts, which were then replicated by regulators in the region, such as Colombia and Bolivia.

Only yesterday, the Argentine authorities have launched the alert, while there are so many local laboratories with the ingredient, alone or in combination, sold by the Chinese manufacturer Zhejiang Huahai Pharmaceutical.

"The ANMAT communicates that after badyzing the available scientific evidence according to the precautionary and uncertain principles of the active pharmaceutical ingredient valsartan prepared by the manufacturer Zhejiang Huahai Pharmaceutical Co. Ltd., ChannanSite, RC-317016, China, proceeded to a withdrawal from the preventive market The measure reached batches of laboratories Richmond, Dr. Lazar and Cia, Temis Lostaló, Baliarda, Elea.Pixel, Internacional Argentino and Monte Verde

The Anmat recommends that patients on treatment with any of these lots monitor and recommend that patients who take any of the drugs included in the list, "Do not interrupt" treatment and consult your doctor. You can call toll-free 0800-333-1234, Monday to Friday from 8 am to 8 pm, Saturdays, Sundays and public holidays from 10 am to midnight, or send an e-mail to


[email protected]